SEC Form 4 · accession 0001209191-18-052831
SUTRO BIOPHARMA, INC. · STRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Farah Champsi
10% Owner
Daniel Janney
Director · 10% Owner
Guy P Nohra
10% Owner
Alta Partners VIII, L.P.
10% Owner
Alta Partners Management VIII, LLC
10% Owner
Period of report
Oct 1, 2018
Accepted (ET)
Oct 1, 2018 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 1, 2018 | C | 589,661 | — | A | 589,661 | D | |
| Common StockF3,F2 | Oct 1, 2018 | C | 458,331 | — | A | 1,047,992 | D | |
| Common StockF4,F2 | Oct 1, 2018 | C | 382,698 | — | A | 1,430,690 | D | |
| Common StockF5,F2 | Oct 1, 2018 | C | 514,211 | — | A | 1,944,901 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2,F1 | — | Oct 1, 2018 | C | 10,201,769 | D | — | — | Common Stock | 589,661 | 0 | D |
| Series C Preferred StockF2,F3 | — | Oct 1, 2018 | C | 12,387,324 | D | — | — | Common Stock | 458,331 | 0 | D |
| Series D Preferred StockF2,F4 | — | Oct 1, 2018 | C | 9,449,318 | D | — | — | Common Stock | 382,698 | 0 | D |
| Series E Preferred StockF2,F5 | — | Oct 1, 2018 | C | 18,698,578 | D | — | — | Common Stock | 514,211 | 0 | D |
Explanation of responses
- F1Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
- F2The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
- F3Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- F4Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
- F5Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.